MacroGenics (MGNX) to Release Quarterly Earnings on Tuesday

Key Points

• MacroGenics is set to release its Q2 2025 earnings results on August 5th, with expectations of reporting a loss of ($0.59) per share and revenue of $28.06 million.
• The company's latest earnings report showed a loss of ($0.65) EPS, missing estimates, but revenue was higher than expected at $13.19 million.
• Analysts maintain a consensus rating of "Hold" for MacroGenics with a price target average of $5.71, reflecting recent adjustments from various equity research firms.

MacroGenics (NASDAQ:MGNX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $28.06 million for the quarter.

MacroGenics (NASDAQ:MGNX - Get Free Report) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). MacroGenics had a negative net margin of 36.23% and a negative return on equity of 59.84%. The business had revenue of $13.19 million for the quarter, compared to the consensus estimate of $9.59 million. On average, analysts expect MacroGenics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Stock Up 1.3%

MGNX stock traded up $0.02 during trading on Friday, hitting $1.58. 1,046,407 shares of the company's stock traded hands, compared to its average volume of 952,531. MacroGenics has a 52 week low of $0.99 and a 52 week high of $5.10. The stock has a fifty day moving average price of $1.49 and a two-hundred day moving average price of $1.87. The stock has a market capitalization of $99.68 million, a price-to-earnings ratio of -1.78 and a beta of 1.59.

Hedge Funds Weigh In On MacroGenics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Amundi bought a new position in MacroGenics in the 1st quarter valued at about $272,000. Jones Financial Companies Lllp lifted its holdings in MacroGenics by 456,243.3% in the 1st quarter. Jones Financial Companies Lllp now owns 136,903 shares of the biopharmaceutical company's stock valued at $174,000 after acquiring an additional 136,873 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in MacroGenics by 90.0% in the 1st quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company's stock valued at $87,000 after acquiring an additional 32,398 shares during the last quarter. Institutional investors own 96.89% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on MGNX shares. B. Riley lowered their target price on shares of MacroGenics from $5.00 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, May 20th. Stifel Nicolaus lowered their price target on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating for the company in a research report on Wednesday, May 14th. Wall Street Zen upgraded shares of MacroGenics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, Barclays restated an "overweight" rating and set a $3.00 price target (down previously from $8.00) on shares of MacroGenics in a research report on Wednesday, May 14th. Seven research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $5.33.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.